Shukra Pharma.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE551C01044
NSEID:
BSEID: 524632

INR

18.62

-0.38 (-2.0%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 7.11 k

Click here to access the older version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Divi's Lab.

Cipla

Kwality Pharma

Sun Pharma.Inds.

Torrent Pharma

Fermenta Biotec.

Shukra Pharma.

Anuh Pharma

Mankind Pharma

Wanbury

Sudarshan Pharma

Why is Shukra Pharmaceuticals Ltd ?

Negative results in Dec 24

NET SALES(Latest six months) At Rs 16.14 cr has Grown at -62.92%
PAT(Q) At Rs 3.16 cr has Fallen at -12.5% (vs previous 4Q average)

With ROE of 15.1, it has a Very Expensive valuation with a 15.3 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 133.00%, its profits have fallen by -55.9%

Despite the size of the company, domestic mutual funds hold only 0% of the company

Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shukra Pharma. for you?

Low Risk, High Return

Absolute

Risk Adjusted

Volatility

Shukra Pharma.

133.0%

154.65

0.86%

SENSEX

0.45%

0.03

14.48%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

23.74%

EBIT Growth (5y)

45.59%

EBIT to Interest (avg)

4.44

Debt to EBITDA (avg)

1.64

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.71

Tax Ratio

25.68%

Dividend Payout Ratio

5.91%

Pledged Shares

Institutional Holding

0.11%

ROCE (avg)

5.87%

ROE (avg)

11.29%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

102

Industry P/E

Price to Book Value

15.32

EV to EBIT

112.49

EV to EBITDA

82.91

EV to Capital Employed

20.95

EV to Sales

27.04

PEG Ratio

Dividend Yield

0.53%

ROCE (Latest)

33.47%

ROE (Latest)

15.07%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-14What is not working for the Company

NET SALES(Latest six months)

At Rs 16.14 cr has Grown at -62.92%

PAT(Q)

At Rs 3.16 cr has Fallen at -12.5% (vs previous 4Q average

Loading Valuation Snapshot...

Here's what is not working for Shukra Pharma.

Net Sales - Latest six months

At Rs 16.14 cr has Grown at -62.92%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs 3.16 cr has Fallen at -12.5% (vs previous 4Q average)

over average PAT of the previous four quarters of Rs 3.61 Cr

MOJO Watch

Near term PAT trend is very negative

PAT (Rs Cr)